159 related articles for article (PubMed ID: 38007223)
21. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
[TBL] [Abstract][Full Text] [Related]
22. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
[TBL] [Abstract][Full Text] [Related]
23. Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model.
Meester RGS; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; de Jonge L; Toes-Zoutendijk E; Kooyker A; Nieboer D; Ramakers CR; Spaander MCW; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Nagtegaal ID; Dekker E; van Leerdam ME; Lansdorp-Vogelaar I;
Gut; 2023 Jan; 72(1):101-108. PubMed ID: 35537811
[TBL] [Abstract][Full Text] [Related]
24. Service evaluation of faecal immunochemical testing and anaemia for risk stratification in the 2-week-wait pathway for colorectal cancer.
Chapman C; Bunce J; Oliver S; Ng O; Tangri A; Rogers R; Logan RF; Humes DJ; Banerjea A
BJS Open; 2019 Jun; 3(3):395-402. PubMed ID: 31183456
[TBL] [Abstract][Full Text] [Related]
25. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
[TBL] [Abstract][Full Text] [Related]
26. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
27. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
[TBL] [Abstract][Full Text] [Related]
28. Early clinical outcomes of a rapid colorectal cancer diagnosis pathway using faecal immunochemical testing in Nottingham.
Chapman C; Thomas C; Morling J; Tangri A; Oliver S; Simpson JA; Humes DJ; Banerjea A
Colorectal Dis; 2020 Jun; 22(6):679-688. PubMed ID: 31876975
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the faecal haemoglobin concentrations and diagnostic accuracy in patients suspected with colorectal cancer and serious bowel disease as reported on four different faecal immunochemical test systems.
Benton SC; Piggott C; Zahoor Z; O'Driscoll S; Fraser CG; D'Souza N; Chen M; Georgiou Delisle T; Abulafi M
Clin Chem Lab Med; 2022 Jul; 60(8):1278-1286. PubMed ID: 35637625
[TBL] [Abstract][Full Text] [Related]
30. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
31. Socioeconomic inequalities in interval colorectal cancer are explained by differences in faecal haemoglobin concentration and age: a register-based cohort study.
Deding U; Kobaek-Larsen M; Bøggild H; Kaalby L; Thygesen MK; Baatrup G
BMJ Open Gastroenterol; 2023 May; 10(1):. PubMed ID: 37230536
[TBL] [Abstract][Full Text] [Related]
32. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
33. Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England.
Crooks CJ; Banerjea A; Jones J; Chapman C; Oliver S; West J; Humes DJ
Aliment Pharmacol Ther; 2023 Aug; 58(4):443-452. PubMed ID: 37421214
[TBL] [Abstract][Full Text] [Related]
34. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
35. Combining the quantitative faecal immunochemical test and full blood count reliably rules out colorectal cancer in a symptomatic patient referral pathway.
Johnstone MS; Burton P; Kourounis G; Winter J; Crighton E; Mansouri D; Witherspoon P; Smith K; McSorley ST
Int J Colorectal Dis; 2022 Feb; 37(2):457-466. PubMed ID: 34932152
[TBL] [Abstract][Full Text] [Related]
36. Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.
Chapman CJ; Banerjea A; Humes DJ; Allen J; Oliver S; Ford A; Hardy K; Djedovic N; Logan RF; Morling JR
Clin Chem Lab Med; 2021 Mar; 59(4):721-728. PubMed ID: 33112776
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
[TBL] [Abstract][Full Text] [Related]
38. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
[TBL] [Abstract][Full Text] [Related]
39. Faecal immunochemical testing and blood tests for prioritization of urgent colorectal cancer referrals in symptomatic patients: a 2-year evaluation.
Bailey JA; Weller J; Chapman CJ; Ford A; Hardy K; Oliver S; Morling JR; Simpson JA; Humes DJ; Banerjea A
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33693553
[TBL] [Abstract][Full Text] [Related]
40. 'Low' faecal immunochemical test (FIT) colorectal cancer: a 4-year comparison of the Nottingham '4F' protocol with FIT10 in symptomatic patients.
Bailey JA; Morton AJ; Jones J; Chapman CJ; Oliver S; Morling JR; Patel H; Humes DJ; Banerjea A
Colorectal Dis; 2024 Feb; 26(2):309-316. PubMed ID: 38173125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
